Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery – Cannabiz
Pharmaceutical CBD clinical trial development represents important progress in cannabis therapeutics, though patients should maintain realistic expectations about timing and superiority over current protocols. Understanding the distinction between…
Starting Federally-Backed Cannabis Clinical Trials in the USA
The opening of federally-backed cannabis clinical trials marks a pivotal moment for evidence-based cannabis medicine. This new infrastructure enables rigorous research previously hindered by federal restrictions. Clinicians should monitor these…
DOJ Schedule III cannabis order creates uncertainty for D.C.’s medical self-certification program
The DOJ Schedule III cannabis order creates regulatory uncertainty for D.C.’s medical self-certification program. This federal scheduling change may disrupt patient access to medical cannabis. Clinicians and patients must understand the implications of…
Feds Ease Cannabis Restrictions and Expand Research Options
Federal cannabis research policy changes are easing restrictions and opening new options for researchers. These changes could accelerate high-quality clinical evidence generation. Practitioners may soon benefit from more robust data to guide therapeutic…
Federal Reclassification of Medical Marijuana Opens New Research Doors for Colorado Scientists
Federal rescheduling medical marijuana from Schedule I to Schedule III removes significant regulatory barriers. This change enables researchers to conduct controlled studies needed for evidence-based treatment. The new classification opens doors for…
Joshua S. Bauchner Discusses Psychedelics Policy at Cannabis Research Conference
This article highlights psychedelics policy developments 2026 and their implications for clinical access. Cross-pollination between cannabis and psychedelic policies signals regulatory convergence. Clinicians should monitor these developments as they…
Sudden Cannabis Reclassification Leaves Maryland Industry, Regulators Confused
Maryland cannabis reclassification has caused confusion among industry regulators and patients. This sudden change affects medical cannabis patient access and regulatory clarity. Clinicians and patients are urged to seek guidance during this transition.
Federal shift on cannabis classification draws mixed reaction – ABC11 Raleigh-Durham
The federal cannabis classification change from Schedule I to Schedule II could remove barriers to medical research. This shift may accelerate therapeutic development and improve clinical guidance. Clinicians are advised to monitor emerging evidence as…
Medical Marijuana Reclassified Under Federal Law, Sparking Debate Over Research, Taxes and Health Impacts
The cannabis schedule ii reclassification clinical implications are significant for medical research and patient care. This federal change removes barriers to controlled trials, enabling better evidence generation. Clinicians can anticipate improved data…
Federal Bill Would Create Cannabis Research Protections – Ganjapreneur
Cannabis research protections are critical to overcoming federal scheduling conflicts that have limited scientific studies. This federal bill aims to reduce regulatory barriers and promote high-quality cannabis research. Improved protections could expand…